Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.73 |
| ▸ | ATM | Q13315 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ANPEP | P15144 | 1/20 | 0.45 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL688633 | 1.00 | MEN1 (0.73) | MEN1KMT2AATMMAPTKDM4E | |
| SCHEMBL5241128 | 1.00 | MEN1 (0.73) | MEN1KMT2AATMMAPTKDM4E | |
| SCHEMBL488658 | 0.98 | MEN1 (0.68) | MEN1KMT2AATMMAPTKDM4E | |
| SCHEMBL5241239 | 0.98 | MEN1 (0.68) | MEN1KMT2AATMMAPTKDM4E | |
| SCHEMBL488845 | 0.98 | MEN1 (0.68) | MEN1KMT2AATMMAPTKDM4E | |
| Ammonia Solution, Strong SCHEMBL488859 | 0.95 | MEN1 (0.65) | MEN1KMT2AATMMAPTKDM4E | |
| SCHEMBL719936 | 0.87 | MEN1 (0.52) | MEN1KMT2AATMMAPTKDM4E | |
| SCHEMBL11118757 | 0.85 | MEN1 (1.00) | MEN1KMT2AATMMAPTKDM4E | |
| SCHEMBL10895166 | 0.82 | MEN1 (0.94) | MEN1KMT2AATMMAPTKDM4E | |
| Trifluoroacetic Acid SCHEMBL5243779 | 0.81 | ATM (0.50) | MEN1KMT2AATMMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1455777-B1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 2007-11-21 | — | — | EP | claimed |
| EP-1455777-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 2004-09-15 | — | — | EP | claimed |
| WO-2003055478-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-07-10 | — | — | WO | claimed |
| CN-119954828-A | Parallel ring compound and preparation and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-116322699-B | Parallel ring compound and preparation and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2025-02-11 | — | — | CN | disclosed |
| US-20240294545-A1 | A CLASS OF FUSED RING COMPOUNDS, AND PREPARATION AND USE THEREOF | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD (CN) | 2024-09-05 | — | — | US | disclosed |
| EP-4219499-A1 | A CLASS OF FUSED RING COMPOUNDS, AND PREPARATION AND USE THEREOF | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2023-08-02 | — | — | EP | disclosed |
| CN-116322699-A | Parallel ring compound and preparation and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2023-06-23 | — | — | CN | disclosed |
| WO-2022063303-A1 | A CLASS OF FUSED RING COMPOUNDS, AND PREPARATION AND USE THEREOF | 石药集团中奇制药技术（石家庄）有限公司 | 2022-03-31 | — | — | WO | disclosed |
| WO-2005049023-A1 | GLYT1 TRANSPORTER INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-06-02 | — | — | WO | disclosed |
| EP-1455777-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003055478-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294545-A1 | A CLASS OF FUSED RING COMPOUNDS, AND PREPARATION AND USE THEREOF | ATM, CHEK2, CHEK1 | MEN1 1511/4885KMT2A 1137/4885ATM 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.